BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Announces $300K Private Placement and Warrant Extension

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company focused on imaging-based products for breast cancer care, announced plans for a non-brokered private placement of up to 1.2 million units at $0.25 each to raise gross proceeds of up to $300,000. Each unit will include one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. The Company also extended the expiry of 2,841,325 warrants issued in September 2023 by one year to September 20, 2026, with all other terms unchanged. The warrant extension remains subject to final CSE approval.

To view the full press release, visit https://ibn.fm/kV1Wl

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — MindWalk Holdings Corp. (NASDAQ: HYFT) Announces 2.3 Million Share Repurchase Program

MindWalk Holdings (NASDAQ: HYFT), a bio-native AI company, announced that its Board of Directors has…

14 hours ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P…

4 days ago

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Appoints Dr. Joel Gagnier as Chief Science Officer to Advance AI-Driven Health Research

Fifty 1 Labs (OTC: FITY), a cutting-edge innovator at the intersection of artificial intelligence, clinical…

5 days ago

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a…

5 days ago

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application…

5 days ago

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL, NXPLW) Issues Q4 Shareholder Update Highlighting Cost Reductions, Healthcare Expansion, and Growth Across Core Channels 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

5 days ago